CN109096368B - 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用 - Google Patents
一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用 Download PDFInfo
- Publication number
- CN109096368B CN109096368B CN201811162358.9A CN201811162358A CN109096368B CN 109096368 B CN109096368 B CN 109096368B CN 201811162358 A CN201811162358 A CN 201811162358A CN 109096368 B CN109096368 B CN 109096368B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- antioxidant
- liver
- cells
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 78
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 58
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 56
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 21
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 18
- 210000004185 liver Anatomy 0.000 title claims abstract description 16
- 230000002633 protecting effect Effects 0.000 title claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 55
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000002443 hepatoprotective effect Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 230000000254 damaging effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 18
- 230000006378 damage Effects 0.000 abstract description 11
- 210000005229 liver cell Anatomy 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 5
- 239000001301 oxygen Substances 0.000 abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 abstract description 5
- 230000005779 cell damage Effects 0.000 abstract description 2
- 208000037887 cell injury Diseases 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 14
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 6
- 210000001700 mitochondrial membrane Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- -1 tyrosine amino acid Chemical class 0.000 description 4
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 3
- 239000008366 buffered solution Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000001857 fluorescence decay curve Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- QFJAZXGJBIMYLJ-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;ethane-1,2-diamine Chemical compound NCCN.OC(=O)C(O)C(O)C(O)=O QFJAZXGJBIMYLJ-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- 230000006036 negative regulation of mitochondrial membrane potential Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用。多肽的氨基酸序列如下：Tyr‑Phe‑Leu‑Pro。本发明中合成肽的抗氧化能力通过氧自由基吸收能力实验（ORAC）评价，乙醇可诱导肝细胞（LO2）造成一定程度损伤，该LO2细胞损伤模型评价合成肽的护肝效果，结果表明合成肽可降低乙醇对LO2细胞的损伤作用，在预防和治疗酒精性肝病上有广泛的应用前景。
Description
技术领域
本发明涉及保健品和药物领域，具体涉及一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用。
背景技术
随着生活水平的提高及膳食结构的改变,酒精性肝病(alcoholic liverdisease,ALD)的发病率逐年上升。酒精性脂肪肝(alcoholic fatty liver,AFL)是酒精性肝病的一种，是由于长期饮用酒精导致酒精性肝损伤，其主要原因是乙醇在肝细胞内代谢产生的毒性代谢产物及其引起的代谢紊乱，其可能会发展成酒精性肝炎、肝纤维化甚至是肝硬化。酒精性脂肪肝是酒精性肝病早期的最显著病理变化，现常以营养支持、降血脂、不饱和脂肪酸和磷脂类药物治疗，但治疗效果不佳且部分药物副作用明显，因此对其有明显治疗效果的药物及控制效果的保健品已成为国内外研究的热点。
AFL主要是由于酒精在细胞内代谢过程中生成乙醛有关，长期摄人酒精可以使肝细胞线粒体功能紊乱，使氧化乙醛的能力下降，而乙醇的氧化速度不变甚至提高，造成乙醛生成与降解不平衡，导致肝内乙醛含量增加，乙醛可与蛋白质形成复合物，对肝细胞产生损伤的作用，且该复合物作对于机体是异物，诱导机体自身免疫系统，加重肝细胞的损伤。肝微粒体乙醇氧化酶系统被激活后，产生的活性氧会直接对肝细胞造成氧化损伤。
活性肽在调控人的生长发育、免疫调节和新陈代谢中具有关键作用，其广泛地存在于各种生物体内，现也有为其特殊功效而人工合成的活性肽。活性肽具有主动吸收、吸收速度快、吸收完整、低耗等优点，并且它的生理功能优于氨基酸和蛋白质，所以具有一定功能的肽类食品是国际上研究的热点，日本、欧洲、美国都推出了各种具有特殊功能的食品和食品添加剂。在专利CN201110193662.1中，香川恭一等人通过对小鼠的动物实验发现多肽Trp-Thr-Gln-Arg(WTQR)抑制了血清中AST和ALT活性的上升，同时抑制了肝脂质的中性脂肪、总胆固醇和游离脂肪酸的积累，改善了肝机能；杨浩然等人发现的乳源免疫调节肽(Pro-Gly-Pro-Ile-Asn,PG-PIPN)在小鼠模型中，能显著降低加药组小鼠的血清AST和ALT含量，并且加药组小鼠的MDA含量降低、SOD和GSH-PX含量明显升高，说明该肽对肝细胞的保护作用与自由基的清除，提高机体抗氧化能力有关。以上说明活性肽对于ALD的防治具有较大的潜力。
发明内容
为了克服现有技术的缺点和不足，本发明的目的在于提供了一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用。本发明提供的多肽，可以作为功能因子应用到护肝保健品和药品的开发上。
本发明的目的通过如下技术方案实现。
一种具有抗氧化活性的多肽，氨基酸序列为Tyr-Phe-Leu-Pro，或者YFLP，其中，Tyr或Y表示英文名称为Tyrosine，中文名称为酪氨酸的氨基酸的相应残基；Phe或F表示英文名称为Phenylalanine，中文名称为苯丙氨酸的氨基酸的相应残基；Leu或L表示英文名称为Leucine，中文名称为亮氨酸的氨基酸的相应残基；Pro或P表示英文名称为Proline，中文名称为脯氨酸的氨基酸的相应残基。
进一步的，所述多肽是具有抗氧化和护肝活性多肽的基因。其中，UAC或UAU为酪氨酸的氨基酸相应基因密码子，UUC或UUU为苯丙氨酸的氨基酸相应基因密码子，UUA、CUG、CUA或CUC为亮氨酸的氨基酸相应基因密码子，CCG、CCA、CCU或CCC为脯氨酸的氨基酸相应基因密码子。
本发明还提供了一种具有抗氧化活性的多肽在降低乙醇对LO2细胞的损伤作用中的应用。
进一步的，所述应用包括在制备预防和治疗酒精性肝病的功能性食品、保健品及药品中的应用。
进一步的，所述应用还包括基于预防和治疗酒精性肝病在药学上能够接受的载体或促血脑屏障穿越因子制备成丸剂、胶囊剂、片剂或注射制剂。
进一步的，发明所述的氨基酸序列采用标准Fmoc方案，选用2-chlorotritylchloride resin树脂进行固相合成。同时也可通过基因工程技术合成，将编码基因接入到载体中，再将载体转录到原核表达体系大肠杆菌中或真核表达体系酵母中进行表达，然后对目标多肽进行分离纯化，获得一种同时具备抗氧化和护肝活性的多肽。
进一步的，本发明首先通过氧自由基吸收能力实验(ORAC)检测了合成多肽的抗氧化活性，发现其供氢能力强，同时作用于乙醇诱导的肝细胞(LO2)损伤模型，发现其在预防和治疗酒精性肝病上有广泛应用前景。
与现有技术相比，本发明具有如下优点和有益效果：
本发明中合成肽的抗氧化能力通过氧自由基吸收能力实验(ORAC)评价，乙醇可诱导肝细胞(LO2)造成一定程度损伤，该LO2细胞损伤模型评价合成肽的护肝效果，结果表明合成肽可降低乙醇对LO2细胞的损伤作用，在预防和治疗酒精性肝病上有广泛的应用前景。
附图说明
图1为序列为YFLP的多肽分子结构式。
图2为多肽YFLP的HPLC图。
图3为多肽YFLP的ESI-MS图。
图4为多肽YFLP对乙醇诱导LO2细胞毒性的影响对比图(纵坐标为细胞存活率，横坐标为合成多肽浓度)。
图5为不同浓度下多肽对乙醇诱导LO2细胞毒性影响的对比图(纵坐标为细胞存活率)。
图6为多肽对乙醇诱导LO2细胞线粒体膜电位影响的对比图(横坐标为单体荧光强度，纵坐标为聚集体荧光强度)。
具体实施方式
本发明公开了一种多肽及其应用。本领域技术人员可以借鉴本文内容，适当改进工艺参数实现。特别需要指出的是，所有类似的替换和改动对本领域技术人员来说是显而易见的，它们都被视为包括在本发明。本发明的方法及产品已经通过较佳实施例进行了描述，相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法进行改动或适当变更与组合，来实现和应用本发明技术。
实施例1：多肽固相合成
1、树脂选型
(1)采用标准Fomc方案，选用0.0125mmol，2-chlorotrityl chloride resin树脂，按照氨基酸序列YFLP的序列特征，加入0.3mol第一个Fmoc保护氨基酸，将DCC和5％(质量分数)DMAP加入到反应器振荡反应，用NMP冲洗树脂除去多余保护氨基酸。
(2)选用0.0125mmol，Wang树脂，方法同上；
2、合成过程
采用标准Fomc方案，选用偶合率较高的2-chlorotrityl chloride resin树脂，按照氨基酸序列YFLP的序列特征，使肽链从C端逐个向N端延伸，各氨基酸的用量为0.1mol，加入0.3molFmoc保护氨基酸，每步缩合都加入HOBT活化保护氨基酸的羧基，每步缩合采用20％哌啶DMF溶液(15ml/g)，处理20min，去除Fmoc保护基。肽侧链合成后，将含有树脂的肽链加入到如下反应液中：二氯甲烷(99％)三氟乙酸(1％)(体积分数)，将肽链从树脂上切割下来。再次将多肽加入到反应液：三氟乙酸(94.5％)、酒石酸乙二胺(2.5％)、蒸馏水(2％)、TIS(1％)(体积分数)中反应2h，脱去侧链保护基。所合成的多肽经高效液相色谱仪纯化，纯度达到99％以上，并经ESI-MS鉴定结构(如表1、图2和图3所示)。
表1
实施例2：合成多肽的ORAC值测定
氧化自由基吸收能力(Oxygen radical absorbance capacity,ORAC)是一种基于氢原子转移机理评价抗氧化能力的方法，被认为接近生物体抗氧化功能的方法。ORAC反应在37℃的75mM磷酸盐缓冲溶液环境中进行，合成多肽(YFLP)、还原性谷胱甘肽(GSH)、荧光素和AAPH自由基均溶解在75mM的磷酸盐缓冲溶液，其中缓冲溶液的pH值为7.4，其终浓度分别为20mg/L，20mg/L，78nM和9.95mM。以Trolox作为标准抗氧化物，其终浓度梯度为0.5-4.2μM，并以GSH作为阳性对照。将合成肽、GSH分别与荧光素混合，并在37℃条件下保温20分钟，之后加入偶氮化合物AAPH，在激发波长485nm，发射波长538nm处检测荧光强度，检测时长为3h，获取荧光衰退曲线。抗氧化剂的氧自由基吸收能力ORAC值通过荧光衰退曲线的保护面积与标准抗氧化物质(Trolox)的保护面积相比得到。ORAC值以Trolox当量表达，结果如表2所示。
表2合成多肽YFLP、GSH的ORAC值
实施例3：合成多肽作用于乙醇诱导肝细胞损伤模型的护肝应用
取处于对数生长期的LO2细胞接种于96孔细胞板中，每孔5000个细胞，置于CO2培养箱中培养24h后，实验组加入合成多肽浓度分别为0.25、0.5、0.75、1、1.25mmol/L的培养液，空白对照组加等量的培养液，每组设3个平行，放回培养箱继续培养24h。每孔加20μLMTT溶液(5mg/mL)，于培养箱孵育4h，弃上清，每孔加入150μL DMSO，在490nm波长下测各孔的吸光值OD。计算不同乙醇浓度处理后各组细胞的存活率：
计算结果如图4所示。图4为多肽YFLP对乙醇诱导LO2细胞毒性的影响对比图，采用单因素ANOVA来检验合成肽与不含肽对照组统计学差异以及多肽不同剂量之间的统计学差异；其中：ns表示P>0.05；*#表示P<0.05。
实施例4：合成多肽作用于乙醇诱导肝细胞损伤模型的护肝应用
将处于对数生长期的LO2细胞按照5000个/孔密度种于96孔板，置于细胞培养箱中铺板24h后，使其重新贴壁。实验组加入浓度为0.5mmol/L的合成多肽培养液预孵育24h，模型组加入等量的培养液，孵育24h，弃上清，实验组加入同时含有0.5mmol/L的合成多肽和0.8mol/L乙醇的培养液，模型组加入0.8mol/L乙醇的培养液，继续培养24h，空白对照组始终用培养液培养。每孔加20μL MTT溶液(5mg/mL)，于培养箱孵育4h，弃上清，每孔加入150μLDMSO，在490nm波长下测各孔的吸光值OD。计算各组细胞的存活率(如图5所示)。
实施例5：合成多肽作用于乙醇诱导肝细胞损伤模型的护肝应用
将处于对数生长期的LO2细胞按照5000个/孔密度种于96孔板，置于细胞培养箱中铺板24h后，使其重新贴壁。实验组加入浓度为1mmol/L的合成多肽培养液预孵育24h，模型组加入等量的培养液，孵育24h，弃上清，实验组加入同时含有1mmol/L的合成多肽和0.8mol/L乙醇的培养液，模型组加入0.8mol/L乙醇的培养液，继续培养24h，空白对照组始终用培养液培养。每孔加20μL MTT溶液(5mg/mL)，于培养箱孵育4h，弃上清，每孔加入150μLDMSO，在490nm波长下测各孔的吸光值OD。计算各组细胞的存活率(如图5所示)。
实施例6：线粒体膜电位检测评价多肽对乙醇致LO2细胞的保护作用
取处于对数生长期的LO2细胞接种于12孔细胞板中，每孔50000个细胞，置于CO2培养箱中培养24h后，实验组1mmol/L的合成多肽预孵育24h，模型组加入等量的培养液，孵育24h，弃上清，实验组加入同时含有1mmol/L合成多肽和0.8mol/L乙醇的培养液，模型组加入0.8mol/L乙醇的培养液，继续培养24h，空白对照组始终用培养液培养。之后用胰酶消化并收集各孔细胞离心，加0.5ml JC-1染色工作液染色半小时，用PBS溶液洗2次，待测。JC-1是一种线粒体荧光探针，能够依赖电势能在线粒体基质聚合。在功能正常的线粒体中，线粒体跨膜电位较高，JC-1在电势能的作用下形成聚合物，发出橙红色荧光。当线粒体功能紊乱时，线粒体膜电位会下降甚至丧失，JC-1在线粒体基质中无法聚集，只能以单体形式分散于细胞中，呈现绿色荧光。可根据JC-1染色后的细胞荧光颜色变化来检测线粒体膜电位的变化，检测结果如图6所示。
合成多肽的高剂量组(1mM)对细胞模型进行干预后，与模型组相比，LO2细胞的细胞存活率显著提高(P<0.05)，而订剂量组(0.5mM)与模型组没有显著性差异。线粒体膜电位实验表明，合成多肽可保护乙醇诱导LO2细胞所导致的线粒体膜电位(m)下降，减缓由于乙醇造成线粒体功能紊乱影响。上述结果表明，本发明中的合成多肽在达到一定浓度时候，可以抑制乙醇诱导的LO2细胞存活率降低，具有护肝作用，可应用于制备预防和治疗酒精性肝病领域。
序列表
<110> 华南理工大学
<120> 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 4
<212> PRT
<213> 四肽(Tetrapeptide)
<400> 1
Tyr Phe Leu Pro
1
Claims (3)
1.一种同时具有抗氧化和护肝活性的多肽的应用，其特征在于：在制备预防和治疗酒精性肝病的药品中的应用；所述氨基酸序列为Tyr-Phe-Leu-Pro，如SEQ ID NO：1所示。
2.根据权利要求1所述的一种同时具有抗氧化和护肝活性的多肽的应用，其特征在于该多肽能降低乙醇对LO2细胞的损伤作用。
3.根据权利要求1所述的一种同时具有抗氧化和护肝活性的多肽的应用，其特征在于，所述预防和治疗酒精性肝病的药品包括在药学上能够接受的载体，所述药品的剂型为成丸剂、胶囊剂、片剂或注射制剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811162358.9A CN109096368B (zh) | 2018-09-30 | 2018-09-30 | 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811162358.9A CN109096368B (zh) | 2018-09-30 | 2018-09-30 | 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109096368A CN109096368A (zh) | 2018-12-28 |
| CN109096368B true CN109096368B (zh) | 2021-07-20 |
Family
ID=64868156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811162358.9A Active CN109096368B (zh) | 2018-09-30 | 2018-09-30 | 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109096368B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114731985B (zh) * | 2022-03-29 | 2023-09-26 | 华南理工大学 | 一种代谢相关脂肪性肝病非人灵长类动物模型的构建方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2840407B1 (fr) * | 2002-05-31 | 2008-07-18 | Commissariat Energie Atomique | Methode de criblage de banques de biomolecules et ses applications |
| AU2003285892A1 (en) * | 2002-10-15 | 2004-05-04 | Bristol-Myers Squibb Company | Bace binding peptides and uses thereof |
| CN101495513B (zh) * | 2004-10-19 | 2014-08-06 | 安姆根有限公司 | 促血管生成素-2特异性结合剂 |
| CN102807602B (zh) * | 2011-06-03 | 2014-06-18 | 香川恭一 | 肝障碍改善用肽及其组合物 |
| US20140349943A1 (en) * | 2011-10-13 | 2014-11-27 | Thomas Gadek | Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions |
-
2018
- 2018-09-30 CN CN201811162358.9A patent/CN109096368B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109096368A (zh) | 2018-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161201A (en) | Signalling molecules derived from hcg for modulating gene expression | |
| CN111647043B (zh) | 含有Hyp-Gly序列的一类抗血小板和抗血栓功能的寡肽 | |
| CN101519427B (zh) | 具有内皮素受体拮抗活性的肽类衍生物及其药物组合物和用途 | |
| CN108676073B (zh) | 一种抗肥胖十肽llvvypwtqr及其应用 | |
| CN107847551A (zh) | 具有抗病毒作用的肽和包含其的组合物 | |
| CN111533800B (zh) | 新型生长激素释放激素类似肽改构和二聚体化制备及其应用 | |
| CN107849091B (zh) | 能够在人脂肪衍生的干细胞和肝细胞中抑制丙肝病毒复制的肽及其衍生物 | |
| CN109096368B (zh) | 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用 | |
| CN116535463B (zh) | 活性肽及其组合物和用途 | |
| CN110713521B (zh) | 多肽cak18n及其促进肝再生和抑制肝细胞凋亡的用途 | |
| CN111363006A (zh) | 一种灵芝菌丝体降压肽及其制备方法 | |
| CN106883299A (zh) | 脂肪组织靶向多肽及其制备方法和应用 | |
| CN108752421B (zh) | 一种合成多肽及其合成方法与应用与编码该合成多肽的基因 | |
| CN109517033B (zh) | 活性肽、重组载体、重组细胞、抗炎组合物及其制备方法和应用 | |
| CN113480597A (zh) | 一种来源于紫苏籽粕的ace抑制肽及其制备方法与应用 | |
| CN110028557A (zh) | 一种Ce6标记的双链抗菌肽及其合成方法和应用 | |
| CN101265292B (zh) | 多肽类物质、其制备方法及其用途 | |
| CN1336381A (zh) | 一种天花粉蛋白突变体及制备方法 | |
| CN114657162B (zh) | 一种具有血管内皮细胞保护功能的抗氧化五肽及其应用 | |
| CN117720621B (zh) | α-淀粉酶抑制肽及其应用 | |
| CN101890010B (zh) | 一种吡啶甲酰胺衍生物在制备抗肿瘤药物中的应用 | |
| AU2021106957A4 (en) | Application of Anchovy Peptide-catechin Conjugate in Improving Memory | |
| RU2223113C1 (ru) | Пептид, обладающий регулирующей биологической активностью на белковый синтез в гепатоцитах | |
| CN107353344A (zh) | 一种能特异地杀死活化b细胞型弥漫性大b细胞淋巴瘤的多肽及其应用 | |
| WO2021142710A1 (zh) | 一种灵芝菌丝体降压肽及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| OL01 | Intention to license declared | ||
| OL01 | Intention to license declared |